Home > Publications Database > [18F]FDG-PET/CT Imaging for Response Characterisation of Experimental Melanomas to Anti-PD-L1/Anti-CTLA-4 Immunotherapy. > print

001     284041
005     20260217125403.0
024 7 _ |2 doi
|a 10.1007/s11307-025-02056-7
024 7 _ |2 pmid
|a pmid:41102571
024 7 _ |2 ISSN
|a 1536-1632
024 7 _ |2 ISSN
|a 1860-2002
037 _ _ |a DZNE-2026-00076
041 _ _ |a English
082 _ _ |a 570
100 1 _ |0 0000-0002-2668-360X
|a Antons, Melissa J
|b 0
245 _ _ |a [18F]FDG-PET/CT Imaging for Response Characterisation of Experimental Melanomas to Anti-PD-L1/Anti-CTLA-4 Immunotherapy.
260 _ _ |a Cham
|b Springer Nature Switzerland
|c 2025
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1770119975_10793
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a Immune checkpoint inhibition has shown promising results in malignant melanoma, but not all patients respond equally well, necessitating early, accurate monitoring of immunotherapy response. [18F]FDG-PET/CT aids in characterising therapy response beyond morphology, but validated imaging biomarkers for immunotherapy response remain scarce. This study investigated three-time point [18F]FDG-PET/CT to monitor combined anti-PD-L1/anti-CTLA-4 immunotherapy in murine melanoma allografts and compared quantitative in vivo imaging biomarkers with ex vivo biomarkers from multiparametric immunohistochemistry at each time point.Melanoma cells (B16-F10) were injected subcutaneously into C57BL/6 mice (n = 40). Seven days post-inoculation, baseline [18F]FDG-PET/CT was conducted. Animals were randomized into two groups; the therapy group received 5 i.p.-injections of anti-PD-L1/anti-CTLA-4 (20 µg/kg) on days 7, 9, 11, 13 and 15 after tumor cell inoculation. The control group received sham treatment. PET/CT was performed at baseline (day 7 post inoculation), follow-up 1(day 13; FU-1) and follow-up 2 (day 19; FU-2). Tumor allografts were harvested at each time point for immunohistochemistry (CD8, Ki-67, TUNEL) to validate imaging parameters (MTV, SUVmax).At FU-1, the therapy group exhibited significantly lower MTV than the control group (p = 0.004). At FU-2, MTV and SUVmax were significantly lower (MTV: p = 0.008; SUVmax: p = 0.0003) compared to controls. Ex vivo analysis revealed significant anti-tumor effects in the therapy group, with higher apoptosis rates (FU-1: p = 0.012; FU-2: p = 0.001), more CD8-positive T-cells (FU-2: p = 0.003) and lower tumor cell proliferation (FU-1: p = 0.012; FU-2: p = 0.012).Multi-time point [18F]FDG-PET/CT allowed for early non-invasive monitoring of combined anti-PD-L1/anti-CTLA-4 immunotherapy in experimental melanomas, validated by multiparametric immunohistochemistry with significant pro-immunogenic, pro-apoptotic and anti-proliferative effects.
536 _ _ |0 G:(DE-HGF)POF4-352
|a 352 - Disease Mechanisms (POF4-352)
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |2 Other
|a Immunohistochemistry
650 _ 7 |2 Other
|a Immunotherapy
650 _ 7 |2 Other
|a Melanoma
650 _ 7 |2 Other
|a [18F]FDG-PET/CT
650 _ 7 |0 0Z5B2CJX4D
|2 NLM Chemicals
|a Fluorodeoxyglucose F18
650 _ 7 |2 NLM Chemicals
|a CTLA-4 Antigen
650 _ 7 |2 NLM Chemicals
|a B7-H1 Antigen
650 _ 7 |2 NLM Chemicals
|a Immune Checkpoint Inhibitors
650 _ 2 |2 MeSH
|a Animals
650 _ 2 |2 MeSH
|a Positron Emission Tomography Computed Tomography
650 _ 2 |2 MeSH
|a Fluorodeoxyglucose F18: chemistry
650 _ 2 |2 MeSH
|a Immunotherapy
650 _ 2 |2 MeSH
|a CTLA-4 Antigen: antagonists & inhibitors
650 _ 2 |2 MeSH
|a CTLA-4 Antigen: immunology
650 _ 2 |2 MeSH
|a Mice, Inbred C57BL
650 _ 2 |2 MeSH
|a B7-H1 Antigen: antagonists & inhibitors
650 _ 2 |2 MeSH
|a B7-H1 Antigen: immunology
650 _ 2 |2 MeSH
|a Cell Line, Tumor
650 _ 2 |2 MeSH
|a Melanoma, Experimental: diagnostic imaging
650 _ 2 |2 MeSH
|a Melanoma, Experimental: therapy
650 _ 2 |2 MeSH
|a Melanoma, Experimental: pathology
650 _ 2 |2 MeSH
|a Melanoma, Experimental: immunology
650 _ 2 |2 MeSH
|a Mice
650 _ 2 |2 MeSH
|a Female
650 _ 2 |2 MeSH
|a Immune Checkpoint Inhibitors: therapeutic use
650 _ 2 |2 MeSH
|a Immune Checkpoint Inhibitors: pharmacology
700 1 _ |a Kloiber-Langhorst, Sandra
|b 1
700 1 _ |a Hirner-Eppeneder, Heidrun
|b 2
700 1 _ |a Schaefer, Rebecca
|b 3
700 1 _ |a Stueckl, Jennifer
|b 4
700 1 _ |a Palumbo, Giovanna
|b 5
700 1 _ |a Oos, Rosel
|b 6
700 1 _ |a Herr, Felix L
|b 7
700 1 _ |a Lindner, Simon
|b 8
700 1 _ |a Ziegler, Sibylle
|b 9
700 1 _ |0 P:(DE-2719)9001539
|a Brendel, Matthias
|b 10
|u dzne
700 1 _ |a Ricke, Jens
|b 11
700 1 _ |a Werner, Rudolf A
|b 12
700 1 _ |a Heimer, Maurice M
|b 13
700 1 _ |a Cyran, Clemens C
|b 14
773 _ _ |0 PERI:(DE-600)2079211-6
|a 10.1007/s11307-025-02056-7
|g Vol. 27, no. 6, p. 1006 - 1014
|n 6
|p 1006 - 1014
|t Molecular imaging & biology
|v 27
|x 1536-1632
|y 2025
856 4 _ |u https://pub.dzne.de/record/284041/files/DZNE-2026-00076_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/284041/files/DZNE-2026-00076_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:284041
|p VDB
910 1 _ |0 I:(DE-588)1065079516
|6 P:(DE-2719)9001539
|a Deutsches Zentrum für Neurodegenerative Erkrankungen
|b 10
|k DZNE
913 1 _ |0 G:(DE-HGF)POF4-352
|1 G:(DE-HGF)POF4-350
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|v Disease Mechanisms
|x 0
914 1 _ |y 2025
915 _ _ |0 StatID:(DE-HGF)3002
|2 StatID
|a DEAL Springer
|d 2024-12-20
|w ger
915 _ _ |0 StatID:(DE-HGF)3002
|2 StatID
|a DEAL Springer
|d 2024-12-20
|w ger
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2024-12-20
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2024-12-20
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |0 StatID:(DE-HGF)1110
|2 StatID
|a DBCoverage
|b Current Contents - Clinical Medicine
|d 2024-12-20
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b MOL IMAGING BIOL : 2022
|d 2024-12-20
915 _ _ |0 StatID:(DE-HGF)0600
|2 StatID
|a DBCoverage
|b Ebsco Academic Search
|d 2024-12-20
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b ASC
|d 2024-12-20
915 _ _ |0 StatID:(DE-HGF)9900
|2 StatID
|a IF < 5
|d 2024-12-20
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21